European Equity pre-Market Summary - 7th September 2026: European bourses look set for a muted open, with volumes light as the US takes a holiday
European equities face a muted open on September 7, 2026, highlighted by Tata Motors' EUR 3.82bn Iveco buyout offer, AstraZeneca's FDA approval, and Novartis trial disappointments.
News detail
Stories AstraZeneca (AZN LN): Camizestrant in combination with a CDK 4/6 inhibitor has been approved in the US for breast cancer treatment. EssilorLuxottica (EL FP) -1.0%: CEO has reportedly streamlined senior management following a bust-up with the founder's son, and as the Co. pushes into North America, the FT reports. Novartis (NOVN SW) -5.3%: Pelacarsen phase III Lp(a) HORIZON trial did not meet its primary endpoints. M&A Iveco Group (IVG IM): Tata Motors (TMCV IS) has launched an open offer for Iveco Group shares at EUR 14.10/shr, valuing the Italian commercial vehicle manufacturer at around EUR 3.82bln. The numbers after the Co. & ticker are the pre-market indication via Tradegate
Related stocks
2 stocksWhat do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
